Feasibility of in vivo (18)F-florbetaben PET/MR imaging of human carotid amyloid-β.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 28321471)

Published in Eur J Nucl Med Mol Imaging on March 21, 2017

Authors

Jan Bucerius1,2,3,4, Henryk Barthel5, Solveig Tiepolt5, Peter Werner5, Judith C Sluimer6, Joachim E Wildberger7,8, Marianne Patt5, Swen Hesse5,9, Hermann-Josef Gertz10, Erik A L Biessen6, Felix M Mottaghy7,11, Osama Sabri5

Author Affiliations

1: Department of Radiology/Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. jan.bucerius@mumc.nl.
2: Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands. jan.bucerius@mumc.nl.
3: Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany. jan.bucerius@mumc.nl.
4: Department of Nuclear Medicine/Radiology and Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC+), P. Debyelaan 25, 6229 HX, Maastricht, The Netherlands. jan.bucerius@mumc.nl.
5: Department of Nuclear Medicine, Leipzig University Medical Centre, Leipzig, Germany.
6: Department of Pathology, Experimental Vascular Pathology, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
7: Department of Radiology/Nuclear Medicine, Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
8: Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Center (MUMC+), Maastricht, The Netherlands.
9: Integrated Treatment and Research Centre (IFB) Adiposity Diseases, Leipzig University Medical Centre, Leipzig, Germany.
10: Department of Psychiatry, Leipzig University Medical Centre, Leipzig, Germany.
11: Department of Nuclear Medicine, University Hospital RWTH Aachen, Aachen, Germany.

Articles cited by this

Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (1991) 49.03

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet (2007) 20.57

Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol (2000) 14.59

Atherosclerosis. the road ahead. Cell (2001) 11.88

Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage. Arterioscler Thromb Vasc Biol (2005) 4.29

In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006) 3.91

Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80

Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet (2004) 3.51

Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol (2008) 3.24

beta-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature (1996) 2.82

Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. J Nucl Med (2008) 2.52

Platelet phagocytosis and processing of beta-amyloid precursor protein as a mechanism of macrophage activation in atherosclerosis. Circ Res (2002) 1.68

Relationships among regional arterial inflammation, calcification, risk factors, and biomarkers: a prospective fluorodeoxyglucose positron-emission tomography/computed tomography imaging study. Circ Cardiovasc Imaging (2009) 1.66

Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. J Am Coll Cardiol (2007) 1.53

Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol (2015) 1.48

Feasibility of [18F]-2-Fluoro-A85380-PET imaging of human vascular nicotinic acetylcholine receptors in vivo. JACC Cardiovasc Imaging (2012) 1.48

11C-Pittsburgh B PET imaging in cardiac amyloidosis. JACC Cardiovasc Imaging (2014) 1.45

Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.38

Atherosclerosis, dementia, and Alzheimer disease in the Baltimore Longitudinal Study of Aging cohort. Ann Neurol (2010) 1.32

Oxidized low density lipoprotein and innate immune receptors. Curr Opin Lipidol (2003) 1.26

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study. Alzheimers Dement (2015) 1.20

Radionuclide imaging: a molecular key to the atherosclerotic plaque. J Am Coll Cardiol (2008) 1.08

Expression of inflammatory genes induced by beta-amyloid peptides in human brain endothelial cells and in Alzheimer's brain is mediated by the JNK-AP1 signaling pathway. Neurobiol Dis (2008) 1.07

Alzheimer disease beta-amyloid activity mimics cholesterol oxidase. J Clin Invest (2005) 1.04

Proteolytic processing of Alzheimer's disease beta A4 amyloid precursor protein in human platelets. J Biol Chem (1995) 0.99

Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Invest (1998) 0.97

Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J Neural Transm (Vienna) (2005) 0.94

Beta-amyloid imaging with florbetaben. Clin Transl Imaging (2015) 0.89

Impact of cardiovascular risk factors on vessel wall inflammation and calcified plaque burden differs across vascular beds: a PET-CT study. Int J Cardiovasc Imaging (2013) 0.88

Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. Biochim Biophys Acta (2011) 0.86